Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Retrospective Analysis of a Multicenter Phase III Study

Fabrizio Carnevale-Schianca, Wendy Leisenring, Paul J. Martin, Terry Furlong, Gary Schoch, Claudio Anasetti, Frederick R. Appelbaum, Paul A. Carpenter, H. Joachim Deeg, Hans Peter Kiem, Rainer Storb, George B. McDonald, Richard A. Nash

Research output: Contribution to journalArticle

Abstract

Because morbidity early after hematopoietic cell transplantation (HCT) results in large part from the development of acute graft-versus-host disease (GVHD), we previously proposed that a longitudinal assessment of morbidity involving the skin, liver, and gastrointestinal (GI) tract might provide a more complete, objective approach for comparing 2 arms of open-label randomized clinical trials for acute GVHD prevention. In this study, we determined both morbidity across time and GVHD across time in a retrospective analysis of a database from an open-label randomized clinical trial comparing tacrolimus/methotrexate and cyclosporine/methotrexate after myeloablative conditioning and marrow transplantation from HLA-matched unrelated donors. The results confirm differences in overall morbidity across time in patients with peak grade II-IV GVHD compared with those with grade 0-I GVHD, but no significant differences in morbidity associated with grade II GVHD compared with grade 0-I GVHD. We observed less skin morbidity and a trend toward less liver morbidity across time in the tacrolimus group (P = .04 and .09, respectively), but not for GI morbidity or overall morbidity, despite significantly decreased skin and liver stages and overall grades of GVHD across time in this group. Thus, our objective assessment of differences in morbidity (regardless of cause) as a measure of acute GVHD in a randomized clinical trial of acute GVHD prevention has only limited utility. The difficulty of demonstrating clinical benefits from objective parameters, such as survival and morbidity, and the subjectivity of grading acute GVHD emphasize the need for blinded assessments in clinical trials of GVHD prevention.

Original languageEnglish
Pages (from-to)749-756
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Cell Transplantation
Graft vs Host Disease
Morbidity
Randomized Controlled Trials
Tacrolimus
Methotrexate
Skin
Liver
Transplantation Conditioning
Unrelated Donors
Needs Assessment
Cyclosporine
Gastrointestinal Tract
Bone Marrow
Clinical Trials
Databases

Keywords

  • Cyclosporine
  • Graft-versus-host disease
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation : Retrospective Analysis of a Multicenter Phase III Study. / Carnevale-Schianca, Fabrizio; Leisenring, Wendy; Martin, Paul J.; Furlong, Terry; Schoch, Gary; Anasetti, Claudio; Appelbaum, Frederick R.; Carpenter, Paul A.; Deeg, H. Joachim; Kiem, Hans Peter; Storb, Rainer; McDonald, George B.; Nash, Richard A.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 6, 06.2009, p. 749-756.

Research output: Contribution to journalArticle

Carnevale-Schianca, Fabrizio ; Leisenring, Wendy ; Martin, Paul J. ; Furlong, Terry ; Schoch, Gary ; Anasetti, Claudio ; Appelbaum, Frederick R. ; Carpenter, Paul A. ; Deeg, H. Joachim ; Kiem, Hans Peter ; Storb, Rainer ; McDonald, George B. ; Nash, Richard A. / Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation : Retrospective Analysis of a Multicenter Phase III Study. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 6. pp. 749-756.
@article{7e48d81e1cb14d70b136c0a429dc07eb,
title = "Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Retrospective Analysis of a Multicenter Phase III Study",
abstract = "Because morbidity early after hematopoietic cell transplantation (HCT) results in large part from the development of acute graft-versus-host disease (GVHD), we previously proposed that a longitudinal assessment of morbidity involving the skin, liver, and gastrointestinal (GI) tract might provide a more complete, objective approach for comparing 2 arms of open-label randomized clinical trials for acute GVHD prevention. In this study, we determined both morbidity across time and GVHD across time in a retrospective analysis of a database from an open-label randomized clinical trial comparing tacrolimus/methotrexate and cyclosporine/methotrexate after myeloablative conditioning and marrow transplantation from HLA-matched unrelated donors. The results confirm differences in overall morbidity across time in patients with peak grade II-IV GVHD compared with those with grade 0-I GVHD, but no significant differences in morbidity associated with grade II GVHD compared with grade 0-I GVHD. We observed less skin morbidity and a trend toward less liver morbidity across time in the tacrolimus group (P = .04 and .09, respectively), but not for GI morbidity or overall morbidity, despite significantly decreased skin and liver stages and overall grades of GVHD across time in this group. Thus, our objective assessment of differences in morbidity (regardless of cause) as a measure of acute GVHD in a randomized clinical trial of acute GVHD prevention has only limited utility. The difficulty of demonstrating clinical benefits from objective parameters, such as survival and morbidity, and the subjectivity of grading acute GVHD emphasize the need for blinded assessments in clinical trials of GVHD prevention.",
keywords = "Cyclosporine, Graft-versus-host disease, Tacrolimus",
author = "Fabrizio Carnevale-Schianca and Wendy Leisenring and Martin, {Paul J.} and Terry Furlong and Gary Schoch and Claudio Anasetti and Appelbaum, {Frederick R.} and Carpenter, {Paul A.} and Deeg, {H. Joachim} and Kiem, {Hans Peter} and Rainer Storb and McDonald, {George B.} and Nash, {Richard A.}",
year = "2009",
month = "6",
doi = "10.1016/j.bbmt.2009.03.009",
language = "English",
volume = "15",
pages = "749--756",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

T2 - Retrospective Analysis of a Multicenter Phase III Study

AU - Carnevale-Schianca, Fabrizio

AU - Leisenring, Wendy

AU - Martin, Paul J.

AU - Furlong, Terry

AU - Schoch, Gary

AU - Anasetti, Claudio

AU - Appelbaum, Frederick R.

AU - Carpenter, Paul A.

AU - Deeg, H. Joachim

AU - Kiem, Hans Peter

AU - Storb, Rainer

AU - McDonald, George B.

AU - Nash, Richard A.

PY - 2009/6

Y1 - 2009/6

N2 - Because morbidity early after hematopoietic cell transplantation (HCT) results in large part from the development of acute graft-versus-host disease (GVHD), we previously proposed that a longitudinal assessment of morbidity involving the skin, liver, and gastrointestinal (GI) tract might provide a more complete, objective approach for comparing 2 arms of open-label randomized clinical trials for acute GVHD prevention. In this study, we determined both morbidity across time and GVHD across time in a retrospective analysis of a database from an open-label randomized clinical trial comparing tacrolimus/methotrexate and cyclosporine/methotrexate after myeloablative conditioning and marrow transplantation from HLA-matched unrelated donors. The results confirm differences in overall morbidity across time in patients with peak grade II-IV GVHD compared with those with grade 0-I GVHD, but no significant differences in morbidity associated with grade II GVHD compared with grade 0-I GVHD. We observed less skin morbidity and a trend toward less liver morbidity across time in the tacrolimus group (P = .04 and .09, respectively), but not for GI morbidity or overall morbidity, despite significantly decreased skin and liver stages and overall grades of GVHD across time in this group. Thus, our objective assessment of differences in morbidity (regardless of cause) as a measure of acute GVHD in a randomized clinical trial of acute GVHD prevention has only limited utility. The difficulty of demonstrating clinical benefits from objective parameters, such as survival and morbidity, and the subjectivity of grading acute GVHD emphasize the need for blinded assessments in clinical trials of GVHD prevention.

AB - Because morbidity early after hematopoietic cell transplantation (HCT) results in large part from the development of acute graft-versus-host disease (GVHD), we previously proposed that a longitudinal assessment of morbidity involving the skin, liver, and gastrointestinal (GI) tract might provide a more complete, objective approach for comparing 2 arms of open-label randomized clinical trials for acute GVHD prevention. In this study, we determined both morbidity across time and GVHD across time in a retrospective analysis of a database from an open-label randomized clinical trial comparing tacrolimus/methotrexate and cyclosporine/methotrexate after myeloablative conditioning and marrow transplantation from HLA-matched unrelated donors. The results confirm differences in overall morbidity across time in patients with peak grade II-IV GVHD compared with those with grade 0-I GVHD, but no significant differences in morbidity associated with grade II GVHD compared with grade 0-I GVHD. We observed less skin morbidity and a trend toward less liver morbidity across time in the tacrolimus group (P = .04 and .09, respectively), but not for GI morbidity or overall morbidity, despite significantly decreased skin and liver stages and overall grades of GVHD across time in this group. Thus, our objective assessment of differences in morbidity (regardless of cause) as a measure of acute GVHD in a randomized clinical trial of acute GVHD prevention has only limited utility. The difficulty of demonstrating clinical benefits from objective parameters, such as survival and morbidity, and the subjectivity of grading acute GVHD emphasize the need for blinded assessments in clinical trials of GVHD prevention.

KW - Cyclosporine

KW - Graft-versus-host disease

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=65549107728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549107728&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.03.009

DO - 10.1016/j.bbmt.2009.03.009

M3 - Article

C2 - 19450760

AN - SCOPUS:65549107728

VL - 15

SP - 749

EP - 756

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -